Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Halozyme Therapeutics Inc. News

    36,56 € -0,73% -0,27 €
    10:43:05 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0DLHS
    ISIN: US40637H1095
    US-Symbol: HALO
    Typ: Aktie

    Halozyme Therapeutics Inc. News

    23.04.24 - PR Newswire
    Halozyme to Report First Quarter 2024 Financial and Operating Results
    Halozyme to Report First Quarter 2024 Financial and Operating Results PR Newswire
    27.02.24 - PR Newswire
    Halozyme to Participate in Upcoming Investor Conferences
    Halozyme to Participate in Upcoming Investor Conferences PR Newswire
    20.02.24 - PR Newswire
    HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
    HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS PR Newswire
    08.02.24 - PR Newswire
    Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
    Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results PR Newswire
    29.01.24 - PR Newswire
    Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-​formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory ...
    18.01.24 - PR Newswire
    Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
    Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-​qvfc) Co-​Formulated with ENHANZE® for Generalized Myasthenia ...
    16.01.24 - PR Newswire
    Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-​formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating ...
    16.01.24 - PR Newswire
    Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
    Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer ...
    12.01.24 - PR Newswire
    Halozyme to Host Investor Business Forum and Long-Term Outlook Call
    Halozyme to Host Investor Business Forum and Long-Term Outlook Call PR Newswire
    27.11.23 - PR Newswire
    Halozyme to Present at Upcoming Investor Conferences
    Halozyme to Present at Upcoming Investor Conferences PR Newswire
    16.11.23 - PR Newswire
    Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
    Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis PR Newswire
    06.11.23 - PR Newswire
    HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
    HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire
    06.11.23 - PR Newswire
    Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
    Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-​Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease PR Newswire
    30.10.23 - PR Newswire
    Halozyme To Report Third Quarter 2023 Financial and Operating Results
    Halozyme To Report Third Quarter 2023 Financial and Operating Results PR Newswire
    19.10.23 - PR Newswire
    Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for ...
    16.10.23 - PR Newswire
    Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
    Update: Halozyme Announces Presentation of Positive Clinical Data of its High-​Volume Auto-​Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual ...
    16.10.23 - PR Newswire
    Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
    Halozyme Announces Positive Clinical Data of its High-​Volume Auto-​Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery PR Newswire
    31.08.23 - PR Newswire
    Halozyme to Present at Upcoming Investor Conferences
    Halozyme to Present at Upcoming Investor Conferences PR Newswire
    29.08.23 - PR Newswire
    Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
    Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain PR Newswire
    08.08.23 - PR Newswire
    HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
    HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire

    Newssuche

    Videos

    newspaper
    09:30 Uhr +18,70%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »